1. Home
  2. IDAI vs QNRX Comparison

IDAI vs QNRX Comparison

Compare IDAI & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo T Stamp Inc.

IDAI

T Stamp Inc.

HOLD

Current Price

$2.37

Market Cap

12.5M

Sector

Technology

ML Signal

HOLD

Logo Quoin Pharmaceuticals Ltd.

QNRX

Quoin Pharmaceuticals Ltd.

HOLD

Current Price

$8.15

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDAI
QNRX
Founded
2016
2018
Country
United States
United States
Employees
96
N/A
Industry
Computer Software: Prepackaged Software
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
14.5M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
IDAI
QNRX
Price
$2.37
$8.15
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
75.0K
20.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.46
N/A
Revenue Next Year
$99.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.43
$0.21
52 Week High
$5.28
$41.80

Technical Indicators

Market Signals
Indicator
IDAI
QNRX
Relative Strength Index (RSI) 36.63 41.52
Support Level $1.90 $8.03
Resistance Level $3.13 $10.10
Average True Range (ATR) 0.25 0.50
MACD 0.02 0.05
Stochastic Oscillator 23.15 10.43

Price Performance

Historical Comparison
IDAI
QNRX

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Share on Social Networks: